The FDA Approval of TIL Therapy and What it Means for Advanced Melanoma

  Рет қаралды 2,931

AIMatMelanoma

AIMatMelanoma

Күн бұрын

An exciting new development in melanoma treatment is the recent FDA approval of Lifileucel (AMTAVGI) therapy, which harnesses the power of the body's own immune cells to recognize and attack melanoma cells.
In this webinar, hosted by Samantha Guild, JD, the esteemed President of AIM at Melanoma, we explore the implications of this newly-approved treatment for melanoma care. Our guest, Allison Betof Warner, is a foremost authority on TIL therapy.
From the National Cancer Institute:
In an event more than three decades in the making, the Food and Drug Administration (FDA) has approved lifileucel (Amtagvi), the first treatment for cancer that uses immune cells called tumor-infiltrating lymphocytes, or TILs. Announced on February 16, 2024, the agency’s decision also makes lifileucel the first cellular therapy to be approved for a solid tumor, the skin cancer melanoma.
The agency’s accelerated approval covers the use of lifileucel for people with advanced melanoma that has gotten worse after treatment with certain immunotherapy drugs or targeted therapies.
As is the case with CAR T-cell therapy, another type of cellular therapy, lifileucel is made using a patient’s own T cells. And with both therapies, the cells are collected at the hospital where the patient is being treated but are sent away to be manufactured into the final treatment.
But there’s a key difference between TILs and CAR T-cell therapies.
For the approved CAR T-cell therapies, the T cells are collected from a patient’s circulating blood. For TIL therapy, by contrast, the T cells are collected from the patient’s tumor.
Lifileucel’s approval was based on findings from a clinical trial sponsored by Iovance Biotherapeutics. Among more than 70 participants who were treated with the lifileucel dose ultimately approved by FDA, nearly one-third had at least some reduction in the size of their tumors (a tumor response), with tumors disappearing completely (a complete response) in several participants.
Moreover, about 40% of those whose cancer responded to lifileucel still had no progression of their cancer a year after receiving the one-time infusion treatment.
TIL therapy was pioneered by Steven Rosenberg, M.D., and his colleagues in NCI’s Surgery Branch. In the late 1980s, Dr. Rosenberg led the first-ever clinical trials of TIL therapy, showing that it could shrink tumors in people with very advanced melanoma. (Dr. Rosenberg was recently given the nation’s highest award for technology and innovation for his work on immunotherapy, including the development of TIL therapy.)
Over the ensuing years, the NCI researchers further refined the process for manufacturing and delivering TIL therapy. In 2011, NCI entered into a cooperative research agreement with Iovance to further develop this particular TIL therapy, including conducting larger clinical trials and developing a manufacturing infrastructure, paving the way for FDA approval.
It’s been a long time coming, Dr. Rosenberg acknowledged. The new approval “is a big step,” he said, one which demonstrates that “cellular therapy is joining the mainstream of cancer treatment.”

Пікірлер: 12
@mahalaxmisharma7323
@mahalaxmisharma7323 5 ай бұрын
Amazing work ! Dr. Alison🎉
@williambanzhof9739
@williambanzhof9739 6 ай бұрын
EXCELLENT! Thanks for presenting!
@agcccggrr
@agcccggrr 6 ай бұрын
Amtagvi needs to be indicated first line.
@SpiritualSchmuck
@SpiritualSchmuck 6 ай бұрын
They have first line trial study with Keytruda I believe and oncologists are over the moon about this.
@911_TruthNow
@911_TruthNow 4 ай бұрын
making the sick person sicker and that is called curing the disease. That is sick.
@artbyfaith
@artbyfaith 4 ай бұрын
My son has Stage 4 metastatic melanoma. He’s getting optivo and Yervoy, but I’m not sure it’s working. The tumor is localized in his left side of his neck. HELP!
@virginian7317
@virginian7317 2 ай бұрын
Who would have thought I, having NETs, would be doing a melanoma treatment. Thank you Dr. Rosenberg!
@robertmontgomery6256
@robertmontgomery6256 4 ай бұрын
Yikes! Isn’t Til the “nuclear option”? Is it used only as a post front line Rx? Not for everyone, right?
@Lisa_RNHealthHub
@Lisa_RNHealthHub 6 ай бұрын
Fascinating!
@codingdevchannel1390
@codingdevchannel1390 6 ай бұрын
Why it is not working 100 percent
@tobbie33
@tobbie33 6 ай бұрын
name a medication that works 100%
@ClintMalvezzi
@ClintMalvezzi 6 ай бұрын
(•)(•) 🎉 this is ground breaking, how does this not have a thousand 🎉🎉comments? This is a situation that everyone should be following. Leaving a . or a * Because god bless women and Gofd bless their TaTa’s (•)(•)
Can We Predict Who Will Respond to Immunotherapy?
26:47
AIMatMelanoma
Рет қаралды 1,3 М.
ASCO 2024: Advances in Melanoma and Related Cancers
1:02:27
AIMatMelanoma
Рет қаралды 1,3 М.
小天使和小丑太会演了!#小丑#天使#家庭#搞笑
00:25
家庭搞笑日记
Рет қаралды 17 МЛН
Officer Rabbit is so bad. He made Luffy deaf. #funny #supersiblings #comedy
00:18
Funny superhero siblings
Рет қаралды 10 МЛН
Win This Dodgeball Game or DIE…
00:36
Alan Chikin Chow
Рет қаралды 37 МЛН
Stanford Health Care
3:24:19
AIMatMelanoma
Рет қаралды 316
Cellular Therapy: TIL Tomorrow and Further
22:14
AIMatMelanoma
Рет қаралды 373
NeoAdjuvant & Adjuvant Therapy: Questions Getting Answered
49:03
Evolution of Immune Intelligent Immunotherapy
31:38
AIMatMelanoma
Рет қаралды 136
The Evolving Role of Surgery in Melanoma Management
21:36
AIMatMelanoma
Рет қаралды 487
Radiation Therapy in Melanoma, Novel Paradigms
20:10
AIMatMelanoma
Рет қаралды 125
The Melanoma Printer for Patients
24:52
AIMatMelanoma
Рет қаралды 195
Melanoma Survivorship Panel : Surviving and Thriving
20:14
AIMatMelanoma
Рет қаралды 133
Behind the Scenes: The Modern Role of Pathology in Melanoma Care
25:09
小天使和小丑太会演了!#小丑#天使#家庭#搞笑
00:25
家庭搞笑日记
Рет қаралды 17 МЛН